From a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...

The US-Iran peace deal is finally about to happen. There is a high probability that global markets will see a relief rally, a part of which...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...

Indian markets saw volatility and closed lower on Wednesday. Key companies are in focus due to significant developments. SoftBank reduced i...

Indian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...

Aurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...

After the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...

Artificial intelligence skill demand in India's Contract Development and Manufacturing Organisation sector is set to surge. Demand for AI s...

Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...

Corporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...

Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defenc...

Indian stock markets may appear stagnant, but opportunities exist in small and midcap stocks. JM Financial's Ashish Chaturmohta highlights ...

Leading analyst Devarsh Vakil suggests Indian markets offer compelling buying opportunities now, with valuations correcting to attractive l...

Gland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving p...

According to industry executives, the modest price hike of 0.6% that the government has allowed on essential medicines effective April 1 is...